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Parkinson's disease (PD) is the second most 
common neurodegenerative disorder after 
Alzheimer’s disease (AD). There is 
considerable consensus that the increased 
production and/or aggregation of 
α-synuclein (α-syn) plays a central role in 
the pathogenesis of PD and related 
synucleinopathies. Current therapeutic 
strategies for treating PD offer mainly 
transient symptomatic relief and aim at the 
restitution of dopamine levels to 
counterbalance the loss of dopaminergic 
neurons. Therefore, the identification and 
development of drug-like molecules that 
block α-synuclein aggregation and prevent 
the loss of dopaminergic neurons is 
desperately needed to treat or slow the 
progression of PD. Herein, we show that 
entacapone (E) and tolcapone (T) are potent 
inhibitors of α-synuclein and Aβ 
oligomerization and fibrillogensis, and also 
protect against extracellular toxicity 
induced by the aggregation of both proteins. 
Comparison of the anti-aggregation 
properties of entacapone and tolcapone with 
the effect of six other catechol-containing 
compounds, dopamine, pyrogallol, gallic 
acid, caffeic acid and quercetin on the 
oligomerization and fibrillization of α-syn 
and β-amyloid (Aβ) demonstrate that the 
catechol moiety is essential for the anti-
amyoidogenic activity. Our findings present 
the first characterization of the 
antiamyloidogenic properties of Tolcapone 
and Entacapone against both alpha-
synuclein and Abeta42 and highlight the 
potential of this class of nitro-catechol 
compounds as anti-amyloidogenic agents. 
Their inhibitory properties, mode of action 
and structural properties suggest that they 
constitute promising lead compounds for 
further optimization. 
 
 
Parkinson's disease (PD) is the second 
most common neurodegenerative disorder after 
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Alzheimer’s disease (AD), affecting nearly 1 - 
2 % of the population 65 years and older. A 
characteristic early pathological change 
associated with PD is the selective loss of 
dopaminergic neurons of the substantia nigra 
pars compacta and other areas of the brain 
resulting in the degeneration of the 
nigro-striatal tract and loss of dopamine (DA) 
(1).  Current therapeutic strategies for treating 
PD offer mainly transient symptomatic relief 
by aiming to restore the loss of dopamine by 
“dopamine replacement therapy”. This is 
accomplished through the administration of 
levodopa (L-DOPA), a direct precursor of DA 
and other drugs that increase the lifetime of 
DA by slowing its metabolism. 
Catechol-O-methyltransferase inhibitors 
(ICOMT), monoamine oxidase B inhibitors 
(IMAOB) and peripheral aromatic L-amino 
acid decarboxylase inhibitors (IADDC) are 
used as adjunctive medications to L-DOPA to 
slow DA degradation and increase the 
availability of brain DA (Scheme 1) (2). 
 
Neuropathologically, PD is characterized 
by the formation of intraneuronal Lewy bodies 
(LBs) and Lewy neuritis (LNs) consisting 
primarily of fibrillar aggregates of α-synuclein 
(α-syn), a 14 kDa “natively unfolded” 
cytosolic protein (3).  Accumulating evidence 
from genetics, animal models, biochemical and 
biophysical studies suggest that α-syn 
aggregation is a toxic event which plays a 
central role in the initiation and/or progression 
of PD (4).  Mutations or increased expression 
of α-syn are associated with early-onset 
familial forms of PD (5-7). Overexpression of 
wild type and disease-associated mutants 
enhances α-syn aggregation and toxicity in 
several animal and cellular models of 
synucleinopathies (8-10). In vitro studies have 
consistently shown that disease-associated 
mutations accelerate and enhance α-syn 
oligomerization (A30P, A53T and E46K) 
and/or fibrillization (A53T and E46K) (11-14). 
 
Despite numerous advances in our 
understanding of the molecular mechanism of 
α-syn aggregation and toxicity in vitro and in 
vivo, we still have limited knowledge about 1) 
the normal physiological function of α-syn; 2) 
the relative contribution of α-syn aggregation 
to the pathogenesis of PD; 3) the identity of the 
toxic α-syn species; 4) the exact mechanism by 
which α-syn contributes to the loss of 
dopaminergic neurons and PD pathology (15-
17). The lack of animal models which 
represent the full spectrum of PD in humans 
and the absence of effective drugs capable of 
blocking α-syn aggregation at different stages 
on the amyloid formation pathway have 
contributed significantly to this knowledge gap 
and slow the pace of drug discovery in PD and 
related disorders.    
 
The ability to block protein aggregation 
using small molecules provides a unique 
opportunity to investigate the link between 
α-syn aggregation and toxicity by assessing 
the functional and cellular consequences of 
blocking aggregation at different stages on the 
amyloid formation pathway. Initial efforts 
aimed at blocking or reversing protein 
aggregation focused on preventing amyloid 
formation or disruption of preformed fibrils as 
a means of promoting their clearance. Several 
classes of small molecules and short peptides 
have been reported as inhibitors or modulators 
of α-syn and amyloid-β (Aβ) fibrillization in 
vitro, including polyphenols such as 
catecholamines, DA and other catechols (18-
22).  Dopamine agonists and IMAO B, 
currently used as anti-parkinsonian agents, 
were also reported to destabilize preformed 
fibrils (23,24).   
 
The aim of this work was to evaluate the 
inhibitory potency of anti-Parkinsonian drugs 
towards the oligomerization, fibrillogenesis 
and toxicity of monomeric and oligomeric 
forms of α-syn. These molecules include two 
nitrocatechols, i.e. entacapone (E) and 
tolcapone (T) (25) (Fig. 1) that have never 
been specifically tested for their anti-
amyloidogenic properties. Herein, were report 
that E and T are potent inhibitors of α-syn and 
Aβ42 oligomerization and fibrillogenesis and 
protect against extracellular toxicity induced 
by the aggregation of both proteins in PC12 
cells. To determine the relative contribution of 
the catechol moiety in these compounds, we 
compared their effect to four other natural 
polyphenols (quercetin (Q), caffeic acid (CA), 
gallic acid (GA) and pyrogallol (P)) known for 
their antioxidant properties (26-29) and 
dopamine (DA), a well-known inhibitor of the 
fibrillization of α-syn and Aβ. Our studies 
present the first characterization of the anti-
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amyloidogenic properties of T and E against 
both α-syn and Aβ42 fibrillization and provide 
new insights into the mechanism of action of 
catchol-containing compounds on the amyloid 
formation pathway of both proteins.  
 
EXPERIMENTAL PROCEDURES 
 
Thioflavin T, gallic acid, quercetin and MTT 
were purchased from Sigma-Aldrich. Dimethyl 
sulfoxide (DMSO) of microbiological quality, 
dopamine, caffeic acid and pyrogallol were 
from Fluka (Buchs, Switzerland). Entacapone 
and tolcapone were kindly donated by Prof. 
Alberto Gasco (Dipartimento della Scienza e 
tecnologia del Farmaco, University of Turin, 
Italy). DMEM, heat-inactivated horse serum, 
fetal bovine serum, gentamicin, insulin, 
NuPAGE 4-12% Bis- Tris gel, goat anti-mouse 
AlexaFluor680 and SilverXpress Silver 
Staining Kit were from Invitrogen. Beta 
amyloid Monoclonal Antibody 6E10 was from 
Covance and nitrocellulose membranes from 
Protran. All chemicals were of analytical grade 
and all solutions were prepared in autoclaved 
distillate water. Compounds solutions were 
prepared in 100 % DMSO (10 mM). Fresh 
solutions were prepared by diluting stock 
solutions in water to achieve a final amount of 
cosolvent less than 1%, in the reaction 
mixtures. 
 
Expression and purification of 
α-synuclein-Human wild type (WT) α-syn was 
expressed as previously described (12). Cells 
were harvested, resuspended in buffer and 
lysed. The supernatant was saved, concentrated 
and loaded onto a Superdex 200 size exclusion 
column. α-syn containing fractions were 
combined, lyophilized and stored at -20 °C 
until use.  
 
Preparation and characterization of 
Aβ42 low molecular weight (LMW) and 
protofibrils (PF)- Aβ42 was synthesized and 
purified by Dr. James I. Elliot at Yale 
University (New Haven, CT). Monomeric 
Aβ42 stock solutions were prepared by 
dissolving the peptide in 6 M Guanidine-HCl 
at concentration of 1 mg/ml and centrifuged at 
8,600 rpm for 5 minutes. Low molecular 
weight (LMW) and protofibril (PF) Aβ42 
stock solutions were prepared by dissolving 
the peptide in 5 % DMSO, 2 M Tris Base pH 
7.6. The mixture was subjected to low speed 
centrifugation at 6000 rpm for 5 minutes. The 
supernatant of Aβ42 containing monomeric, 
LMW and PF was loaded onto a Gel filtration 
column (Superdex 75 HR 10/30 Amersham) 
previously equilibrated with 10 mM Tris 
buffer pH 7.4 (30). The fractions were 
analyzed by SDS-PAGE and protein 
concentration was determined by UV 
absorbance at 280 nm in 10-mm path-length 
cuvettes using the theoretical molar extinction 
coefficient at 280 nm for Aβ42 (1490 M-1 cm-
1) (31). All Aβ42 stock solutions were diluted 
with Tris buffer pH 7.4 to a final peptide 
concentration of 10 μM. Samples of Aβ42 
were incubated at 37 °C in 1.5 mL 
polypropylene sterile tubes, with and without 
different concentrations of inhibitors, at molar 
ratios of Aβ42: inhibitor of 1:0.5 and 1:2.  
 
Preparation of α-syn and Aβ42 
seeds-The seeds were prepared by incubation 
of α-syn peptide solution (20 mM Tris buffer, 
150 mM NaCl (pH 7.4)) and Aβ42 peptide 
solution (5% DMSO, 2 M Tris buffer (pH 7.6) 
at 37 °C under agitation for three days. The 
fibrils were then mechanically fragmented to 
yield narrow distribution of smaller fibrillar 
structures (100-300 nm long) by ultra-
sonication on ice using SONICS Vibra Cell TM 
equipped with a fine tip (20 x 5 second pulses, 
amplitude 40, output watts 6). The sonicated 
fibrils were diluted in 10 mM Tris buffer pH 
7.4. Seeds and monomeric α-syn or Aβ42 were 
incubated for 4 hours at 37 °C with continuous 
shaking, with and without inhibitors, in 
polystyrene black 384 well plates (Nunc, 
USA). 
 
Fibrilization Studies 
Purified, lyophilized α-syn was dissolved 
in 20 mM Tris buffer, 150 mM NaCl. The 
samples of α-syn at a concentration of 100 μM 
(as estimated by spectroscopy) were incubated 
at 37 °C in 1.5 mL sterile polypropylene tubes, 
with continuous shaking, in the absence and 
presence of inhibitors, at a molar ratio of 
α-syn: inhibitors of 1:1, 1:0.5, 1:0.1 and 
1:0.01. Aliquots (10 μL) of the α-syn 
incubations (final protein concentration of 10 
μM), previously incubated at 37 °C with and 
without compounds, were added to 80 μL of 
50 μM Glycine-buffer (pH= 8.5) and 10 μL 
solution of 100 μM. Aliquots of 80 μL of 10 
μM Aβ42 solutions (LMW or PF), previously 
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incubated at 37° C in absence and in presence 
of compounds were added to 10 μL of 100 μM 
ThT and 10 μL of 50 μM Glycine-buffer (pH= 
8.5).  
The time course of α-syn and Aβ42 
fibrillization was measured by the ThT 
fluorescence assay. Fluorescence 
measurements were carried out with a 
spectrofluorometer (Analyst™ AD 96-384, 
Bucher Biotec AG, Basel) at 25 °C using 
polystyrene black 384 well plates. The 
excitation wavelength was set to 450 nm and 
emission was monitored at 485 nm. All 
measurements were done in triplicates by 
performing three identical experiments. 
 
Seeding polymerization assay 
The polymerization of soluble α-syn with or 
without α-syn fibrils added as seeds and Aβ42 
with or without Aβ42 seeds was assayed as 
described elsewhere (32). Nunc 384 
fluorescence plates were filled with 
monomeric and seed protein solutions. 
Compounds of interest (or Tris buffer 
containing DMSO 1% for the control) were 
finally added to the reaction mixture. The plate 
was incubated at 37 °C for 3 hours under 
agitation. The kinetics and extent of 
fibrillization was monitored using the standard 
Thioflavin T (ThT) binding assay as described 
above. The assay was run in triplicate by 
processing three identical plates. 
 
 
Electron microscopy analysis of fibril 
formation 
Aβ and α-syn fibril formation was monitored 
by transmission electron microscopy (TEM). 
Samples for TEM analysis were prepared by 
placing 10 μL of the sample solution on 
formvar-carbon copper grid for 1 min before 
removing the excess solution. The grid was 
washed with two drops of distillated water and 
1 drop of uranyl acetate before staining with 1 
% of fresh uranyl acetate for 30 seconds. The 
grids were thoroughly examined to get an 
overall evaluation of the structures present in 
the sample. Specimens were inspected at 80 
kV using a Philip CIME 12 electron 
microscope. Digitized photographs were 
recorded with a slow scan CCD camera 
(Gatan, Model 679). 
 
NMR spectroscopy 
 
NMR spectra were acquired on a Bruker 
Avance III 600 MHz NMR spectrometer at 
15°C. Measurements were performed using 60 
µM 15N-labeled αS in 20mM Tris, 150 mM 
NaCl pH= 7.4. Two-dimensional 1H-15N 
Heteronuclear Single Quantum Coherence 
(HSQC) spectra were recorded using 256 × 
1024 complex data points in the F1 and F2 
dimensions, with a relaxation delay of 1.0 s 
(33). Sixty-four scans per increment were 
recorded for each spectrum. Spectral widths 
were 1612.9 and 7211.5 Hz in the 15N and 1H 
dimensions, respectively.  
       Spectra were processed with Topspin 1.3 
(Bruker Biospin) and NMRPipe (34). 
Visualization and manipulation were 
performed using the public domain graphics 
program Sparky 3 (34). Resonance 
assignments had been previously obtained 
(35). The addition of 1% DMSO and a small 
change in temperature did not interfere with 
transfer of resonance assignment. 
       2D 1H-15N HSQC spectra were recorded to 
monitor chemical shift changes induced by the 
presence of three compounds (E,Q,T). 
Compounds were freshly dissolved in DMSO 
to high concentration and added to the αS 
sample. The concentration of DMSO did not 
exceed 3% (v/v). Measurements were 
performed for molar ratios of 1:0.5, 1:2 and 
1:10 αS:ligand. For each titration step, a 
reference spectrum was obtained by addition of 
the same amount of DMSO only. Both 
intensity and chemical shift differences were 
analyzed with respect to the DMSO reference 
spectrum. Mean weighted 1H-15N chemical 
shift differences were calculated according to 
Δav = {[(Δδ2HN + Δδ2N/25)]}/2 (35,36) (33). 
 
 
PC12 preparation and toxicity studies 
The rat adrenal gland pheochrompcytoma cell 
line, PC12, were grown at 37 °C in 5% of CO2 
in DMEM supplemented with 6% heat-
inactivated horse serum, 6% of fetal bovine 
serum and Gentamicin 50 µg/ml. 
Exponentially growing PC12 cells (5*104 cells 
per well) were plated in 96-well tissue culture 
plates (Falcon) in a media supplemented with  
2µM insulin and 50 µg/ml gentamicin; the 
cells were co-treated with Aβ42 crude 
preparation (40 µM) and the compounds (40 
µM) at different concentration (5 µM, 10 μM, 
20 µM and 40 μM) for 24 hr at 37°C and in 
5% of CO2; the peptide and the compounds 
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 5 
were added directly in the medium DMEM 
supplement with 2µM insulin and 50 µg/ml 
gentamicin. Given the slow rate of 
spontaneous α-syn fibrillization in vitro, the α-
syn toxicity studies were performed using pre-
aggregated proteins formed in the presence and 
absence of inhibitors. Briefly, the α-syn protein 
was incubated alone for 72 hr at 37 °C under 
agitation conditions alone or in the presence of 
the inhibitors at different molar ratio. At this 
point, α-syn or the α-syn-inhibitor mixtures 
were added directly to the cell culture medium 
(DMEM supplement with 2µM insulin and 
50µg/ml gentamicin) and incubated with PC12 
for 24 hr at 37°C in 5% of CO2. The viability 
of PC12 cells was evaluated by thiazolyl blue 
MTT (37) and luminescent cells assays. The 
MTT assay is based on the conversion of 
tetrazolium salt to formazan (blue compound), 
a reaction that only occurs in viable cells since 
the chemical reaction is carried only by 
mithocondrial dehydrogenases. MTT was 
added at final concentration of 0,5mg/ml for 2 
hr at 37 °C and the formed crystals were 
dissolved using 100µl of solubilization buffer 
containing 30% SDS and 70% isopropanol in 
water. The optical density was determined at 
570 nm using a microplate reader. The 
luminescent cell viability assay is a sensitive 
method of determining the number of viable 
cells in culture based on quantitation of the 
ATP present, an indicator of metabolically 
active cells. The assay procedure involves 
adding the single reagent (Promega CellTiter-
Glo® Reagent) directly to cultured cells. The 
light emission, measured by Safire Instrument, 
is directly proportional to the ATP produced. 
All quantitative data are presented as means 
+/- SE. Statistical analysis between different 
treatments was calculated by using one way 
analysis of variance (ANOVA) followed by 
post-hoc comparison through Bonferroni's test. 
A value of p>0.05 was considered statistically 
significant. 
 
 
RESULTS 
 
Inhibition of α-syn fibrillization by 
entacapone, tolcapone and related catechols. 
α-syn fibril formation is a concentration 
dependent process and occurs readily in vitro 
only under conditions that combine high 
protein concentrations (100-200 µM) and 
mechanical agitation to accelerate the process 
(supplemental Fig. 1). We evaluated the 
fibrillization of human WT α-syn alone under 
agitation in the range of 50-200 µM and a 100 
µM protein concentration was chosen as the 
optimal concentration to assess the inhibitory 
activity of the compounds (Fig. 1). Under these 
conditions, α-syn fibrillization was complete 
after 72-96 hr of incubation at 37 °C.   
To investigate the influence of the two 
nitrocatechols, entacapone (E) and tolcapone 
(T), and the four natural compounds, quercetin 
(Q), caffeic acid (CA), gallic acid (GA) and 
pyrogallol (P) on α-syn aggregation, we 
monitored the fibrillization of α-syn in the 
absence and presence of each compound in the 
concentration range of 1-100 µM using ThT 
fluorescence, SDS-PAGE analysis of soluble 
protein and TEM as a function of time. DA 
was chosen as a reference compound and was 
tested under the same working conditions. As 
shown in Fig. 2, after 72 hr of incubation, all 
compounds tested abolished α-syn fibril 
formation at concentrations of 50 and 100 µM.  
Compounds E, GA and Q exhibited strong 
inhibition of α-syn aggregation even at 
concentrations of 10 µM, with compound T 
demonstrating the greatest inhibition potency 
(Fig. 2A). More than 70-80% reduction of the 
ThT fluorescence signal was observed in all 
samples containing ≥ 10 µM of compounds.  
The ThT results were confirmed by TEM, 
which demonstrated the absence of significant 
amounts of amyloid fibrils in α-syn samples 
incubated with the compounds at 100 µM 
concentrations (Fig. 2B).  After 72 h, WT 
α-syn alone formed extensive fibrillar 
structures with an average diameter of 35 nm. 
In the samples containing 100 µM of E, T, Q, 
CA, GA and P, the number of fibrils was 
significantly reduced, and spherical oligomers 
and short sheared fibrils were observed 
instead. Aggregates formed in the presence of 
the various compounds were morphologically 
distinct from those formed by WT α-syn.  
To further confirm the inhibitory effect 
observed by ThT and TEM assays, we 
quantified the amount of remaining soluble 
protein by SDS-PAGE analysis of the 
supernatant after removal of fibrils and 
insoluble materials by centrifugation. The 
sample containing α-syn alone showed a 
reduction in band intensity corresponding to > 
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 6 
~ 70-80% loss of soluble α-syn after 72 hr of 
incubation at 37 °C, suggesting that the 
majority of soluble α-syn has been converted 
into insoluble fibrils under these conditions. In 
contrast, all samples containing the compounds 
(100 µM) showed levels of soluble protein that 
correspond to the inhibitory effect reported by 
ThT and TEM. At 1:1 molar ratio, more than ~ 
60% of the starting protein remained in 
solution after 72 hr of incubation (Fig. 2A).  
 
Inhibition of the seeding capacity of 
fibrillar α-syn. The process of amyloid fibril 
formation follows a nucleation-dependent 
polymerization mechanism that is 
characterized by an initial lag-time phase 
(nucleation phase), followed by an exponential 
growth phase (polymerization phase) and a 
final plateau (equilibrium phase) (38).  The 
spontaneous breakage of fibrils into smaller 
aggregates or their disassociation by small 
molecules or chaperones is believed to 
contribute to the spreading and acceleration of 
amyloid formation in vivo via a seeding 
mechanism (39,40).  This is supported by in 
vitro and in vivo studies demonstrating that 
amyloid fibril formation is accelerated by the 
addition of preformed aggregates (41,42), 
which act as seeds that nucleate fibril 
formation and growth.  In other words, the 
addition of seeds eliminates the lag phase 
associated with fibril formation. Therefore, 
blocking the seeding capacity of preformed 
fibrils is an attractive strategy for slowing 
amyloid formation and disease progression in 
PD and related disorders. For this purpose, the 
ability of the compounds to inhibit the seeding 
capacity of α-syn fibrils was investigated.  
To produce α-syn seeds, mature α-syn 
fibrils were mechanically disrupted by 
sonication to yield a narrow distribution of 
short fibrils. As expected, addition of small 
amounts of seeds abolished the lag phase and 
accelerated α-syn fibrillization (Fig. 3A). To 
determine the relative potency of the 
compounds towards blocking the seeding 
capacity of α-syn fibrils, 10 and 50 µM of each 
compound was added to a solution of freshly 
prepared monomeric α-syn. Fibrillar seeds at 2 
µM final concentration were then added and 
the kinetics of fibrillization was monitored by 
ThT fluorescence. In the absence of 
compounds, fibrillization proceeds 
immediately to yield a dense network of 
amyloid fibrils. The fibrillization reaction was 
complete within 3 hr as opposed to 72-96 hr in 
the absence of the seeds. At 50 µM 
concentration of E, T, Q, P, and CA (full 
triangles in Fig. 3A) the seeding capacity of 
short α-syn fibrils was abolished by >90%.  
However, only Q and T exhibited a similar 
potency at lower concentrations (10 µM). The 
remaining compounds E, P, CA, GA, and DA 
still showed greater than 60-75% inhibition of 
seeded fibril growth at this concentration. 
These findings were confirmed by TEM, 
which demonstrated the presence of 
predominantly spherical structures and short 
isolated fibrillar assemblies, (Fig. 3B) in 
seeded samples containing 50 µM of the 
compounds compared to extensive fibril 
formation in samples containing only α-syn.  
 
Entacapone (E), tolcapone (T) and 
related catechols do not bind to monomeric 
α-syn. Binding of E, T and Q to monomeric α-
syn was probed using nuclear magnetic 
resonance (NMR) spectroscopy. NMR signals 
of backbone amides constitute excellent probes 
of complex formation providing maps of 
interaction interfaces (43). We monitored the 
position and intensity of the NMR signals of α 
-syn in the presence of E, T and Q for molar 
ratios up to 1:10 α-syn:compound. In the case 
of Q, only a 1:2 ratio was reached due to its 
lower solubility. No significant chemical shift 
changes were observed for any of the 
compounds, with the exception of very minor 
chemical shift changes for His50 and some N-
terminal residues (Fig. 4A,B,C). As the very 
small chemical shift changes observed for 
His50 and the two to three N-terminal residues 
are most likely due to slight changes in pH, the 
NMR data suggest that there is no direct 
interaction of the compounds with the 
backbone of monomeric α-syn.  
Besides the position of NMR signals, their 
intensity is very sensitive to changes in the 
conformational properties of a protein as well 
as its chemical environment. For example, 
signal broadening indicates increased chemical 
exchange. When we compared the intensity of 
NMR signals in 2D 1H-15N HSQC spectra of 
α-syn in the free state and in the presence of 
the compounds E and T, residues in the C-
terminal domain showed a different response 
than those of residues 20-105 (Fig. 4D, E, F). 
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NMR signal intensities in the C-terminal 
domain in the presence of E and T were within 
10-15% of the values in the free state. In 
contrast, a large number of residues in the N-
terminal domain of α-syn, in particular in the 
NAC region showed an increase of up to 30% 
in NMR signal intensity in the presence of E 
and T when compared to the DMSO control 
spectrum. The increased NMR signal 
intensities point to an increase in the backbone 
flexibility of these residues or to a reduced 
amide proton exchange. Interestingly, a similar 
increase in NMR signal intensities was 
observed for residues 22-93 of α-syn in the 
presence of polyamines, which bind to the 
C-terminus of monomeric α-syn (44). 
  
All compounds protect PC12 against α-syn-
induced cell death.  
To investigate the effect of the E and T 
and related compounds in Fig.1 against α-syn-
induced extracellular toxicity on the PC12 
cells, we used a preparation of α-syn which 
was incubated in the presence and/or absence 
of compounds for 72 °C at 37 °C under 
agitating conditions. The α-syn-compound 
mixtures were then added to the cell culture 
media and cell viability was evaluated using 
the MTT assay. The treatment with the pre-
aggregated α-syn (40 μM) showed a reduction 
of cellular viability by ~ 40 % (Fig. 5). α-Syn 
samples which were incubated with inhibitors 
showed a significant increase of cell viability 
in the range of 10-30%. Interestingly, E was 
found to be the most active compound, with a 
protective effect close to 100%. These results 
suggest a direct correlation between the effect 
of these compounds on the fibrillization of α-
syn and protection against α-syn-induced 
extracellular toxicity, which may be linked to 
the compounds ability to block the formation 
of the toxic entity or processes.  
 
 
Entacapone (E), tolcapone (T) and 
related catechols inhibit the conversion of low 
molecular weight (LMW) Aβ42 into fibrils. In 
order to assess the inhibitory specificity of the 
compounds towards α-syn fibrillation, we 
investigated their capacity to inhibit the 
fibrillization of monomeric (LMW) and 
protofibrillar (PF) Aβ42, which were prepared 
freshly by size exclusion chromatography 
(SEC) as described previously (30). Fresh 
monomeric Aβ42 solutions were incubated 
(37°C), with and without compounds at molar 
ratios compound: Aβ42 of 0.5:1 and 2:1 for 24 
hr and 48 hr. In the presence of 5 µM (data not 
shown) and 20 µM of compounds (Fig. 6A), 
Aβ42 fibrillization was decreased by ≥ 50% 
after 48 hr of incubation. Q was found to be 
the most potent compound, showing greater 
than 80% inhibition of Aβ42 fibrillization at 5 
- 20 µM, whereas the remaining compounds 
showed inhibition in the range of 60-70% at 
higher molar ratios (2:1, compound: Aβ42). 
These findings indicated that these compounds 
act by one of the following mechanisms: 1) by 
stabilizing monomeric Aβ; 2) by kinetic 
stabilization aggregation intermediates that 
precede mature fibril formation; or 3) by 
altering the aggregation properties of Aβ42 
such that ThT negative large aggregates are 
formed.   
To determine their mode of action, the 
samples were analyzed by electron 
microscopy. TEM images of LMW Aβ42 
following incubation for 48 hr in the presence 
of compounds indicate E and T stabilize 
distinct aggregate morphologies compared 
with the other compounds (Fig. 6B). 
Negatively stained TEM images of LMW 
alone revealed amyloid fibrils (diameter of 30 
nm) in the sample after 48 hr incubation (Fig. 
6B). Aβ42 solutions containing 20 µM of E 
and T revealed predominantly large networks 
of PF-like structures and the absence of mature 
fibrils. In comparison with E and T, the other 
compounds P, GA, CA and DA appeared to 
exert different effect on Aβ fibrillization. GA 
and CA were shown to stabilize smaller PF 
structures and result in the formation network 
of amorphous aggregates, after 48hr incubation 
at 37 °C. When Q was added to the sample 
containing Aβ42 LMW, we observed the 
formation of predominantly LMW and PF 
species.   
 
Entacapone (E), tolcapone (T) and 
related catechols inhibit the conversion of 
Aβ42 protofibrils (PF) into mature fibrils in a 
specific and concentration dependent 
manner. To test our hypothesis and determine 
if these compounds act by targeting 
intermediates on the amyloid pathway, we 
evaluated their capacity to block the 
conversion of PFs into mature amyloid fibrils.  
PFs are metastable oligomeric intermediates, 
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which have been observed during the in vitro 
fibrillization of Aβ and almost all other 
amyloidogenic proteins (45). During the last 
decade, mounting evidence from in vivo and in 
vitro studies point toward early aggregation 
intermediates, including PFs, as the major 
cytotoxic species responsible for triggering 
neurodegeneration in AD, PD, prion diseases 
and other related diseases (46). Freshly 
isolated PFs were co-incubated with 5 and 20 
µM of compounds and the aggregation was 
monitored by ThT fluorescence and TEM after 
24 hr (data not shown) and 48 hr at 37 °C. 
After 48 hr, the samples containing PFs alone 
showed an increase in ThT signal consistent 
with a conversion of the PFs into mature fibrils 
(Fig. 7A). When PFs were incubated with 20 
µM GA and CA the increase in ThT 
fluorescence observed with PFs alone was 
reduced by approximately 50%. More than 
70% reduction in the ThT signal was observed 
in the samples containing 20 µM of P, E and 
DA suggesting that these compounds are more 
effective at inhibiting the PF to fibril 
conversion. However, co-incubation of PF 
with 20 µM of Q or T resulted in > 80-90 % 
inhibition, with Q being the most potent 
inhibitor of PF growth and fibrillization in the 
series. As expected, TEM analysis of the 
samples containing PFs alone after 48 hr of 
aggregation showed dense networks of fibrils. 
In the presence of Q, T, E, DA, mainly PF-like 
structures, similar to those present at the 
starting conditions were observed, in addition 
to only some isolated short fibrils (Fig. 7B).  
Short fibrils were observed in the presence of 
GA and CA after 48 hr (Fig. 7B), which is 
consistent with the higher ThT signal in these 
samples (Fig. 7A). 
 
Only Entacapone (E), Tolcapone (T) are 
effective in inhibiting the seeding capacity of 
Aβ42. To determine if E, T and related 
compounds can block Aβ42 aggregation at a 
later stage of the fibrillization process, i.e. 
fibril growth, the capacity of the compounds to 
interfere with fibril elongation and the seeding 
capacity of Aβ42 fibrils was evaluated using 
the seeding polymerization assay described 
above. Fibrillar seeds of Aβ42 were prepared 
by fragmenting preformed and purified fibrils 
by sonication. The freshly prepared fibril seeds 
were added to a fresh monomeric solution of 
Aβ42 and co-incubated with each of the 
compounds (20 µΜ). The kinetics of 
fibrillization was followed over a period of 3 
hr with ThT and the structures of the final 
aggregates were characterized by TEM.  
Among all the compounds, only E, T and Q 
showed significant reduction in fibril growth 
and inhibition of the seeding capacity by Aβ42 
fragmented fibrils (Fig. 8). Analysis of these 
samples by TEM revealed predominantly short 
fibrillar structures resembling the fibrillar 
seeds, consistent with the ThT results (data not 
shown). These results further confirm that 
these E, T and Q interfere with the elongation 
and growth of Aβ42 fibrils possibly via direct 
interactions with either Aβ42 seeds or 
monomers or both. After 3 hr incubation, no 
inhibition was observed in the samples 
containing P and CA. Moreover, addition of 
GA and DA to the mixtures containing Aβ42 
monomers and seeds did not affect the rate of 
fibrillization and resulted in only slight 
reduction of the ThT fluorescence signal (Fig. 
8).  
 
Protection against Aβ42-induced toxicity 
in PC12 cells. Previous studies reported that 
natural polyphenols like Q, GA and CA are 
neuroprotective against Aβ toxicity. The 
effects of Q and GA have been studied against 
Αβ42 in primary cultures (47-49) and in vivo 
models of AD (50). Recently, the protective 
role of CA on Aβ-induced toxicity in PC12 
cells was also described (51). We sought to 
determine if there is a correlation between the 
inhibitory potency of the polyphenolic 
compounds on Aβ aggregation and their effect 
on Aβ-induced toxicity in PC12 cells.  The 
compounds were pre-incubated at 
concentrations in the range of 5 -  40 µΜ with 
crude preparation of Αβ42, i.e. preparations 
containing predominantly LMW and PF 
Αβ42. These conditions were chosen to mimic 
the pathological situation in vivo where both 
the LMW and PF species are populated in the 
diseased AD brain.  After incubation with Aβ 
42 for 20 - 30 min, the Aβ -compound 
mixtures were then added to PC12 in cell 
culture media. The cellular viability was 
assessed after 24 hr using MTT and 
luminescent assays (30). All the compounds 
tested did not increase the mortality of PC12 
cells in the absence of Aβ42 even at the 
highest concentration of inhibitors (40 µM, see 
Supplemental Fig.2), demonstrating that the 
compounds do not enhance cell viability on 
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their own over a concentration range of 10 - 40 
µM. The cells were then treated for 24 hr 
either with 40 μM of Αβ42 alone or in the 
presence of 5 µM, 10 µM, 20 μM and 40 μM 
of the compounds (supplemental Fig. 2). 
Exposure of PC12 cells to 40μM of Aβ42 
reduced the cellular viability by approximately 
40% and 50% (Fig. 9) as determined by the 
MTT assay and ATP release, respectively 
(Supplemental Fig. 3) with respect to the 
control (untreated cells). HAt higher 
concentrations of polyphenols (20 μM and 40 
μM) were found to be protective against the 
Aβ42 toxicity but the attenuation of the 
toxicity was less evident when compared to the 
effect observed at low concentration. However, 
P and DA showed a strong protective effect at 
a concentration of 40 μM. At low 
concentration (5 μM) E and T induced a 
significantly (~ 30%) protection against Aβ-
induced toxicity whereas at higher 
concentration (10 µM, 20 µM and 40 µM) we 
found an increase of cellular viability and ATP 
release of approximately 20 %. These 
observations indicate that the protection in the 
co-treatment of the PC12 cells could be related 
to a dual activity of the compounds, i.e. their 
inhibitory activity against Aβ aggregation and 
protection against Aβ-induced cell toxicity.  
 
 
DISCUSSION 
 
Converging evidence from various 
sources, including pathology, genetics, 
biochemistry, cell biology and animal models 
suggest that the aggregation of α-syn in PD 
and Aβ in AD play a critical role in the 
pathogenesis of these complex disorders. 
Hence, strategies aimed at inhibiting and/or 
reducing the aggregation and amyloid fibril 
formation of these proteins represent a viable 
therapeutic strategy to combat and/or prevent 
the progression of neurodegeneration in both 
diseases. Towards identifying potent drug-like 
aggregation inhibitors, E and T, two ICOMT 
currently approved as adjuncts in the therapy 
of PD, and five other catechol-containing small 
molecules (GA, CA, Q, P and DA) were 
selected and their effect on the oligomerization 
and fibrillization of α-syn and Aβ42 was 
investigated using ThT fluorescence, TEM and 
SDS-PAGE analysis.  
Our results demonstrate that all catechol-
containing compounds shown in Fig. 1 
inhibited α-syn and Aβ fibrillization in vitro 
and showed protective effects against α-syn 
and Aβ42-induced toxicity in PC12 cells. At 
1:1 protein to compound ratio, all compounds 
tested showed > 90% inhibition of α-syn 
fibrillization and blocked the growth and 
seeding capacity of α-syn fibrils. However, at 
lower protein to compound ratios (10:5 and 
10:1) only Q, T, E showed the strongest 
inhibition. CA and P were the least effective at 
lower molar ratios and showed only 40-50% 
inhibition of α-syn fibril formation.   
To probe the specificity of these 
compounds towards α-syn, we determined 
their capacity to inhibit the fibrillization of 
Aβ42 monomers, PFs and fibrils. All the 
compounds exhibited reduced (55-75%) 
inhibitory activity against the fibrillization of 
LMW and PF Aβ42, with the exception of Q, 
which resulted in >90% reduction in the 
fibrillization of Aβ42 fibril formation. When 
we examined the effect of these compounds on 
the fibrillization of Aβ42 PFs, we observed 
that T, E, and DA, showed greater inhibition 
(80-90%), with Q being the most effective 
compound. By TEM analysis, we did not 
observe significant differences in the structural 
properties of the aggregates and fibrils formed 
among the various compounds tested. 
There are several mechanisms by which 
these compounds could inhibit amyloid 
formation, including their ability to: 1) 
stabilize the native monomeric state of 
amyloid; 2) target different intermediates on 
the amyloid pathway and block their 
conversion to fibrils; 3) alter the aggregation 
pathway in favour of non-amyloidogenic 
aggregates. In the case of α-syn, both 
SDS-PAGE analysis and TEM analysis 
demonstrate that the presence of these 
compounds enhances the solubility of α-syn 
(Fig. 2). On the other hand, none of the 
compounds tested were shown to stabilize 
monomeric Aβ42, instead the efficacy of these 
compounds appears to be linked to their ability 
to interfere with Aβ42 aggregation at different 
intermediate stages on the amyloid pathway 
(Fig. 6A and Fig. 7A). All compounds tested 
were shown to promote the formation of large 
non-fibrillar aggregates and/or protofibrillar 
species as discerned by TEM (Fig. 6B and Fig. 
7B) and the reduced solubility of Aβ42 in 
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presence of some compounds, despite the fact 
incubation with such compounds results in 
significant reduction in the ThT signals. 
Consistent were the TEM data, we failed to 
detect significant accumulation of monomeric 
Aβ42 after 96 hr of incubation in the presence 
and absence of compounds. Interestingly, each 
of the compounds appears to exert very 
specific effects and show preference for 
targeting different aggregation state on the 
amyloid pathway. For example, while T and E 
were equally effective in blocking the 
fibrillization of Aβ42 LMW and PF and 
showed strong inhibition of Aβ42 fibril growth 
and seeding capacity, DA and Q were most 
effective against the fibrillization of Aβ42 
LMW and PF, but did not show significant 
inhibition of Aβ42 fibril growth and seeding 
capacity. Furthermore, incubation of each 
compound with Aβ42 resulted in the 
accumulation of Aβ42 aggregates of distinct 
size and morphological properties (Fig. 6B and 
Fig. 7B).  
Together, these results suggest that the 
presence of the catechol moiety in these 
compounds is sufficient to impart on them an 
anti-amyloidogenic activity against α-syn and 
Aβ42. However, the TEM and solubility 
studies demonstrate that the compounds 
interfere with the fibrillization of Aβ42 and 
α-syn via distinct mechanisms. This 
hypothesis is further supported by our findings 
that all the compounds showed strong 
inhibition of α-syn fibril growth and seeding 
capacity, whereas only T and E were effective 
in blocking the growth and seeding capacity of 
Aβ42 fibrils. The remaining (P, CA, GA, Q, 
and DA) compounds showed minimal effect 
even at 1:1 molar ratio, in contrast to their 
ability to block the seeding capacity of α-syn 
under similar conditions. To determine if the 
specificity and potency of these compounds is 
mediated by their interaction with specific 
sequences and/or structural motifs within these 
two proteins, we sought to determine which 
residues interact with the most potent 
compounds, Q, T and E using NMR. These 
studies did not show any significant chemical 
shift changes for any of the compounds, with 
the exception of very minor chemical shift 
changes for His50 and some N-terminal 
residues, suggesting that there is no direct 
binding of the compounds to the backbone of 
α-syn in its monomeric state. However, an 
increase in NMR signal intensity was observed 
in the presence of E and T for a large number 
of residues in the N-terminal domain of α-syn, 
in particular in the NAC region. This is in clear 
contrast, to the action of the polyphenol 
(-)-epigallocatechin gallate (EGCG), which 
binds to the backbone of monomeric α-syn and 
Aβ40, decreases the NMR signal intensity of 
monomeric α-syn and redirects both α-syn and 
Aβ40 into unstructured off-pathway oligomers 
(52). EGCG targets the polypeptide main chain 
that is identical in all proteins and easily 
accessible under unfolded conditions (52). In 
contrast, ThT fluorescence, SDS-PAGE and 
TEM measurements indicate that the COMT 
inhibitors appear to target a conformational 
feature of oligomers. Currently it is not known 
what this conformational feature is, but 
hydrophobic patches formed in oligomers in a 
rather unspecific manner could be a potential 
target. Thus, the COMT inhibitors or their 
scaffold are potentially more useful lead 
compounds than EGCG, as they preferentially 
bind to protein aggregates and not to unfolded 
polypeptide backbones. 
 
Entacapone (E), tolcapone (T) and 
related catechols protect against extracellular 
a-syn and Aβ42-induced toxicity in PC12 
cells. To determine if the ability of these 
compounds to block and/or alter the 
fibrillization pathway of Aβ42 and α-syn 
fibrillization could translate into protection 
against Aβ42 and α-syn cellular toxicity, we 
evaluated their protective effect in the cell 
culture using different assays. At 
concentrations that showed significant 
inhibition of Aβ42 and α-syn fibrillization, all 
the compounds were shown to protect PC12 
cells from Aβ42 and α-syn-induced cytoxicity, 
by mechanisms that are directly linked to their 
ability to modulate the fibrillization of both 
proteins.  These results are in agreement with 
previous studies. Several small polyphenol 
molecules were shown to exhibit strong anti-
amyloidgoenic and neuroprotective properties 
in vitro and in vivo. Bastianetto et al. reported 
on the neuroprotective effects of GA and other 
green and black tea catechin gallate against 
Aβ40 in neuronal cell cultures (49). Other 
groups have also demonstrated that cathechol 
and polyphenol compounds as potent anti-
amyloid agents and investigated the chemical 
and structural properties underlying their 
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potency. However, to the best of our 
knowledge the anti-amyloidogenic properties 
of the two nitrocatechols E and T, already 
known for other biological activities, i.e. 
antioxidants and ICOMT, have never been 
described in literature.  
 
     Although there is strong evidence in 
support of the protofibril hypothesis, the exact 
mechanisms by which protofibrils cause 
toxicity and the identity of the toxic species 
remain unknown.  Protofibrils represent a 
heterogeneous mixture of aggregates of 
various size and morphologies, some of which 
are likely to contribute to toxicity.  It is 
noteworthy, that all the fibrillization inhibitors 
reported in the literature, including those that 
protect against Aβ and α-syn toxicity exert 
their effect by acting at an intermediate step 
along the amyloid pathway, i.e. there are no 
known small molecule inhibitors that stabilize 
monomeric Aβ and α-syn.  As shown in 
Figures 6 and 7, the different compounds we 
tested appear to stabilize or induce the 
formation of prefibrillar aggregates of distinct 
morphologies. Together, these results suggest 
that these molecules act by altering the 
structure of the aggregates and diverting toxic 
intermediates towards off-pathway non-toxic 
species.  Studies from several groups have 
shown that small molecules, including inositol 
stereoisomers (53), (-)-epigallocatechin gallate 
(EGCC) (52) as well as Aβ42 derived peptides 
(54) were shown to alter the toxic properties of 
Aβ by stabilizing and/or inducing structural 
remodeling of protofibrillar and fibrillar 
aggregates.  Resveratrol blocks Aβ toxicity 
without inhibiting oligomer formation (55). 
Moreover, recent studies from our group (30) 
and others (56) suggest that amyloid toxicity 
requires an on-going fibrillization process, i.e. 
the presence of protofibrils or fibril is not 
sufficient to cause toxicity unless these species 
are undergoing an on-going fibrillization 
process.  
 
 
Previous studies with DA and other 
catecholamines, e.g. apomorphine (57), linked 
their anti-amyloidogenic properties to their 
ability to undergo rapid autoxidation in 
aqueous solution, suggesting that one or more 
oxidation products is responsible for their 
inhibitor properties (21). However, the two 
major products of the catecholamine oxidation, 
i.e. quinines and aminochromes, are relatively 
unstable and difficult to isolate. In order to 
verify this hypothesis, the 3-methoxytyramine, 
the major metabolite of dopamine, was tested 
in the same working condition and in the 
presence of the two proteins, i.e. α-syn and 
Aβ42. As expected, the results obtained 
confirmed that the methylated derivative of 
dopamine had no effect on the protein 
fibrillization process (data not shown). The 
mechanism by which catechol containing 
compounds block protein fibrillization remains 
controversial.  Conway et al. reported that DA 
stabilise α-syn PFs by forming a DA-α-syn 
adduct (20). More recently, Norris et al. 
suggested a novel mechanism of action in 
which the dopaminochrome, the oxidized 
product of DA, inhibits α-syn fibrillization by 
interacting with the specific amino acid motif 
in the C terminus and NAC region of α-syn 
(21,23,40,58,59). Given the structural 
similarity amongst E, T and other known anti-
amyloidgenic catechol derivatives such as DA 
and Q, it is plausible to speculate that a shared 
mechanism may underlie the effectiveness of 
all these compounds. All seven molecules 
shown in Fig. 1 have in common the fact that 
each possesses at least one aromatic ring with 
catechol moiety. 
  
 
Relevance to α-syn toxicity and Parkinson’s 
disease. Although predominantly a cytosolic 
protein, several lines of evidence suggest a 
potential role of extracellular α-syn in 
mediating α-syn toxicity, Lewy body 
formation and the pathogenesis of PD and 
related synucleinopathies.  These lines of 
evidence include: 1) recent studies from 
different laboratories which have shown that 
some monomeric and/or soluble aggregated 
forms of α-syn are secreted and can be 
detected in the blood plasma and cerebrospinal 
fluids of patients suffering from PD and related 
synucleinopathies (60-63); 2) the fact that 
exogenous aggregated forms of α-syn have 
been shown to induce microglial activation, 
stimulate the production of reactive oxygen 
species (64)),  and pro-inflammatory factors 
(65) and are toxic to mammalian cells and 
primary neurons (66-72); 3) studies which 
have shown that the cellular uptake of 
extracellular α-syn occurs by passive diffusion 
(monomers) or via receptor mediated 
endocytic pathways (73) (oligomers and 
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protofibrils), depending on the aggregation 
state of α-syn (74) 4) the fact that small 
amounts of extracellular α-syn aggregates can 
efficiently catalyze the aggregation of 
intracellular α-syn inclusions. Specifically, 
Luk et al demonstrated that α-syn fibrils, 
prepared from recombinant full length or 
truncated α-syn, were uptaken by cells within 
cultures and act as seeds that catalyzed the 
aggregation and conversion of soluble 
intracellular α-syn into LB-like inclusions (75). 
Finally, 5) Desplats and colleagues 
demonstrated neuron-to-neuron and neuron-to-
glia transmission of monomeric and 
aggregated α-syn species in vivo and in cell 
cultures (76). These studies suggest that the 
release and uptake of monomeric and soluble 
aggregates of α-syn plays a central role in 
inclusion formation, neuronal cell death and 
spreading of α-syn pathology in PD. Therefore, 
targeting the aggregation of extracellular α-syn 
and/or promoting their clearance have emerged 
as viable therapeutic strategies for PD and 
related synucleinopathies. In this regard, the 
identification of small molecules that block or 
reverse the aggregation of extracellular α-syn 
is desirable. Herein, we demonstrated that 
entacapone, tolcapone  and related catechols 
inhibit α-syn fibrillization in vitro and prevent 
the formation of toxic aggregates as discerned 
by their protection against α-syn induced 
extracellular toxicity in PC12 cells.  
 
Currently, the most effective treatment for PD 
continues to be the administration of L-DOPA 
together with a peripheral AADC inhibitor that 
is unable to enter the central nervous system. 
However, the amount of L-DOPA reaching the 
brain after oral administration is very low 
(about 5-10%). Furthermore, the subsequent 
metabolism of L-DOPA by 
catechol-O-methyltransferase (COMT) clearly 
limits its availability in the brain. The two 
COMT inhibitors E and T, approved as 
adjuncts in the therapy of PD, increase the 
availability of L-DOPA for conversion to 
dopamine in the brain (25) mainly by 
preventing the extensive metabolism of 
L-DOPA through O-methylation in the 
periphery (E and T) and partly in brain (T) (77) 
However, the potential for the use of T as 
neuroprotective drug in AD or PD is limited 
due to the fact that it has been shown to cause 
severe hepatotoxicity resulting in its 
withdrawal from the market in many countries 
leaving entacapone as the only COMT 
inhibitor presently available in the clinic for 
the treatment of PD (78). However, recent 
studies demonstrate that tolcapone can be used 
with benefit when the liver function is actively 
monitored (79,80). Although these two 
compounds share the same pharmacophore, 
their pharmacokinetic profiles are remarkably 
different (81). Indeed, studies with rats have 
shown that tolcapone has a longer duration of 
action than entacapone and is both a central 
and peripheral COMT inhibitor, whereas 
entacapone is essentially a peripheral inhibitor 
(82-85). However, the benefits of both 
entacapone and tolcapone in the L-DOPA 
treatment of patients suffering of Parkinson's 
disease were proved (86-88).  
 
Conclusions. In summary, our study showed 
that entacapone and tolcapone are potent 
inhibitors of α-syn and Aβ oligomerization and 
fibrillogensis and protect against extracellular 
toxicity induced by the aggregation of both 
proteins. Our results provide additional 
evidence for the potential of catechols as anti-
amyloidogenic agents and and demonstrate 
that entacapone and tolcapone belong to the 
classes of multifunctional drugs (89) since they 
can inhibit COMT, act as good antioxidants 
and as effective inhibitors of protein 
aggregation (90). Whether the 
anti-amyloidogenic property of entacapone and 
tolcapone and the protection against α-syn 
extracellular toxicity contribute to their clinical 
benefits and enhanced symptomatic treatment 
of PD or not remains to be determined. 
Nonetheless, our findings suggest that the 
structure entacapone and tolcapone constitute 
molecular scaffolds that could guide the 
development of more potent inhibitors of 
amyloid formation and toxicity. Chemical 
modifications of entacapone and tolcapone can 
be envisaged in order to optimize its 
pharmacokinetic profile especially by avoiding 
hepatotoxicity (91), modeling its peripherical 
metabolism and increasing its BBB 
permeation.  
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The abbreviation used are: Aβ42, amyloid beta-(1-42); AD, Alzheimer’s disease; BBB, blood brain 
barrier; ICOMT, Catechol-O-methyltransferase inhibitors; CA, caffeic acid; E, entacapone; GA, gallic 
acid; HPLC, high pressure liquid chromatography; HSQC, heteronuclear single quantum coherence; 
LBs, Lewy bodies; L-DOPA, levodopa; LNs, Lewy neuritis; DA, dopamine; IADDC, dopamine 
receptor agonists and peripheral aromatic L-amino acid decarboxylase inhibitors; IMAOB, 
monoamine oxidase B inhibitors; NMR, nuclear magnetic resonance; PD, Parkinson’s disease; P, 
pyrogallol; Q, quercetin; α-syn, α-synuclein; SEC, size-exclusion chromatography; TEM, 
transmission electron microscopy; ThT, Thioflavin T; T, tolcapone; WT, wild-type. 
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FIGURE LEGENDS 
 
SCHEME 1. Working model illustrating that protein aggregation, i.e. α-syn in PD and Aβ in 
AD, has a central role in the generation of the cascade of events that result in neurodegeneration 
and disease.  
 
Fig. 1. Chemical structure of compounds examined as inhibitors of human WT α-syn and Aβ42 
fibril formation. 
 
Fig. 2. The compounds abolish α-syn fibril formation and increase the soluble forms of α-syn 
after incubation for 72h. (A) Samples of 100 µM α-syn were incubated at 37 °C, with 
continuous shaking, with and without compounds, at molar ratios of α-syn: inhibitor of 1:0.1, 
1:0.5 and 1:1. The time course of protein fibrillization was measured by ThT fluorescence assay 
after incubation for 72 hr. The bar graph represents the amount of fibril formation in absence and 
in presence of the compounds pyrogallol (P), gallic acid (GA), caffeic acid (CA), quercetin (Q), 
tolcapone (T), entacapone (E), and dopamine (DA). The figure shows means of three 
independent experiments ± SD (n=6). The inhibitory effect of the compounds on α-syn 
aggregation was evalueted by SDS-PAGE. Samples of α-syn (100 µM) were incubated with and 
without compounds, at molar ratios of α-syn:inhibitor of 1:1. The bands represent the amount of 
monomeric form of α-syn before incubation and after incubation for 72 hr in the absence and in 
the presence of the compounds. (B) Electron micrographs of negatively stained quaternary 
structures deposited from solutions of α-syn before incubation and after 72 hr incubation at 37°C 
in the absence and in the presence of 100 µM compound. Scale bar represents 200 nm.  
 
Fig. 3. The compounds have an inhibitory effect on the α-syn seeding polymerization. (A) 
Samples of monomeric α-syn (100 µM) were incubated with the seeds (2 µM) at 37°C, with 
continuous shaking, without (a) and with (b-h) 10 µM and 50 µM of compounds pyrogallol (P), 
gallic acid (GA), caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E), and dopamine 
(DA). The time course of protein fibrillization was measured every 30 minutes by ThT 
fluorescence assay for 3 hr. (B) Electron micrographs of negatively stained quaternary structures 
deposited from solutions of seeds and α-syn+seeds after 3hr incubation in the absence and in the 
presence of the compounds (50 µM). Scale bar represents 200 nm.  
 
Fig. 4. Analysis of compound binding to monomeric α-syn by NMR spectroscopy. Changes in 
individual cross-peak positions (panels A, B, C) and intensities (panels D, E, F) of backbone 15N-
1H resonances of α-syn (60 µM) in 2D 1H-15N HSQC spectra in the presence of compound E 
(panels A and D), T (panels B and E) and Q (panels C and F). For compounds E and F, molar 
ratios of 1:10 α-syn:compound were used. Compound Q is less soluble and only the 1:2 α-
syn:compound ratio could be measured. Horizontal lines indicate the average variation of 
chemical shifts observed for α-syn from sample to sample due to slightly different buffer 
conditions. 
 
Fig. 5. Protective effect of the compounds against α-syn induced toxicity in PC12 cells. PC12 cells 
were treated with pre-incubated α-syn (40µM) alone or co-incubated with  5μM of gallic acid 
(GA), caffeic acid (CA), quercetin (Q), tolcapone (T) and entacapone (E) and 40µM of 
pyrogallol (P) and dopamine (D). The cellular viability was evaluated by MTT assay and the 
data were expressed as percentage of the control (non treated cells). The control treatment is set 
to 100%. Bars are means ± S.E. We used # to compare the data to the control and * respect to the 
treatments with α-syn. A:## p< 0.001, B:*** p< 0.001, C:**p< 0.01, D:*p< 0.05. 
 
Fig. 6. The compounds inhibit low molecular weight (LMW) Aβ42 fibril formation. (A) Samples 
of LMW Aβ42 were incubated at 37°C with and without compounds, at molar ratios of Aβ42: 
inhibitor of 1:2. The time course of protein fibrillization was measured by ThT fluorescence 
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assay. The bar graph represents the amount of fibril formation in absence and in presence of the 
compounds pyrogallol (P), gallic acid (GA), caffeic acid (CA), quercetin (Q), tolcapone (T), 
entacapone (E), and dopamine (DA). The samples containing the compounds showed a decrease 
of the ThT fluorescence signal after 48 hr incubation. The figure shows means of three 
independent experiments ± SD (n=6). (B) Electron micrographs of negatively stained quaternary 
structures deposited from solutions of LMW Aβ42 (10 µM) before and after 48 hr incubation at 
37 °C in the absence and in the presence of 20 µM of the compounds listed. Scale bar represents 
200 nm.  
 
Fig. 7. The compounds prevent the conversion of Aβ42 protofibrils (PF) into mature fibrils in a 
specific and concentration-dependent manner. (A) Samples of PF Aβ42 stock solutions were 
prepared by dissolving the peptide in 5 % DMSO, 2 M Tris Base pH 7.6. Samples of Aβ42 were 
incubated at 37 °C with and without compounds, at molar ratios of Aβ42: inhibitor of 1:2. The 
time course of protein fibrillization was measured by ThT fluorescence assay. The bar graph 
represents the amount of fibril formation in absence and in presence of the compounds 
pyrogallol (P), gallic acid (GA), caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E) 
and dopamine (DA). The samples containing the compounds showed a decrease of the ThT 
fluorescence signal after 48 hr incubation. The figure shows means of three independent 
experiments ± SD (n=6). (B) Electron micrographs of negatively stained quaternary structures 
deposited from solutions of PF Aβ42 (10 µM) before incubation and after 48 hr  incubation at 37 
°C in the absence and in the presence of 20 µM of the compounds listed. Scale bar represents 
200 nm.  
 
Fig. 8. The Aβ42 monomeric seeding polymerization assays revealed that Q, E and T have an 
inhibitory effect on the kinetic. Samples of monomeric Aβ42 (10 µM) were incubated with the 
seeds (2 µM) at 37 °C, with continuous shaking, without (A) and with (B-H) 20 µM of 
compounds pyrogallol (P), gallic acid (GA), caffeic acid (CA), quercetin (Q), tolcapone (T), 
entacapone (E), and dopamine (DA). The time course of protein fibrillization was measured 
every 30 minutes by ThT fluorescence assay for 3 hours.  
 
Fig. 9. Protective effect of the compounds against Aβ42–induced toxicity in PC12 cells. PC12 
cells were treated with Aβ42 (40µM) or co-treated in presence of the compounds pyrogallol (P), 
gallic acid (GA), caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E) and dopamine 
(D). The cells were treated with two different compound concentrations: 5 μM and  20 μM  for 
24 h. The cellular viability was evaluated by MTT assay  and the data were expressed as 
percentage of control (non treated cells). The control treatment is set to 100%. Error bars are 
means ±S.E. We used # to compare the data to the control and * respect to the treatments with 
Aβ42 crude preparation. A: ### p<0.001, B: *** p<0.001, C: **p<0.01, D: *p<0.05. The 
statistical value was ### for the treatment with Aβ42 crude preparation respect to the control; the 
statistical values for the compounds were ***p<0.001 for GA (5 μM and 20 μM), CA, Q, E (5 
μM), and **p<0.01 for P (5 μM and 20μM), T (5 μM and 20μM), CA, Q, E and D (20 μM).  
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